GlassScriptPhysician profile
Catherine A Azar
NPI 1083741037
$28,522.92
in general payments reported to CMS, 2019-2025
52 companies · $689 in 2025
The $689 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,735 · 2020: $1,715 · 2021: $21K · 2022: $1,426 · 2023: $653 · 2024: $1,504 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Long Term Medical Supply Or Device Loan: $698 · Consulting Fee: $275 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.92 |
| Long Term Medical Supply Or Device Loan | $697.90 |
| Consulting Fee | $275.00 |
| Education | $251.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19,365.63 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,797.21 | 2019-2023 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $959.94 | 2019 | |
| Genzyme Corporation | $832.29 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $802.10 | 2019-2024 | |
| Macrogenics, INC. | $800.00 | 2021 | |
| Janssen Biotech, INC. | $419.59 | 2019-2025 | Imbruvica, Darzalex, Erleada |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $185.56 | 2020-2024 | Enhertu, Lynparza |
| Incyte Corporation | $178.79 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
| Merck Sharp & Dohme LLC | $175.45 | 2019-2024 | Keytruda, Lynparza |
| Genentech USA, INC. | $135.05 | 2019-2024 | Columvi, Polivy, Lunsumio |
| Celgene Corporation | $107.23 | 2019-2024 | Reblozyl |
| Amgen INC. | $97.58 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Gilead Sciences, INC. | $89.93 | 2019-2024 | Trodelvy |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Azar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.